• It’s the biggest news of the day that put us all to sleep: Pfizer and GSK are creating an HIV company/JV, will try to snag some of the market from Gilead. [Business Week]

• TorreyPines hires banker to explore “strategic options,” will hang on a bit further. [Pharmalive]

• Novartis’ Diovan (valsartan) fails in study, can’t prevent recurrence of atrial fibrillation. [MedPageToday]

• J&J scraps plans for a separate wellness and disease-prevention unit. Good idea. [Reuters]

• Tysabri selling well, Biogen stock up. [Bloomberg]

• Vion Pharmaceuticals’ NDA for Onrigin (laromustine) accepted for review by FDA. [PRNewswire]

• Finally, Amgen wants everyone to look at their preclinical pipeline for AACR. Interesting yes, but c’mon: we want NDA filings/Phase 3 data/approvals/complete responses!!! Zzzzzzzzzzzzz. Wake us up when the conference is over (when’s ASCO btw?) [Xconomy]

Image from all over the freakin’ web

Related Posts